Cargando…

PB2447: PREEMPTIVE TREATMENT WITH PD-1 ANTIBODY FOR ACUTE MYELOID LEUKEMIA/MYELODYSPLASTIC SYNDROME WITH POSITIVE MINIMAL RESIDUAL DISEASE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

Detalles Bibliográficos
Autores principales:	MA, Ling, Sun, Yuqian, Huang, Xiaojun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Publication Only
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429453/ http://dx.doi.org/10.1097/01.HS9.0000976492.22434.77

Ejemplares similares

PB2443: APPLICABILITY OF SHORT TANDEM REPEAT (STR) IN LEUKEMIA PATIENTS RECEIVED ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN THE ERA OF MINIMAL RESIDUAL DISEASE (MRD)
por: Kim, Juhyung, et al.
Publicado: (2023)

Preemptive Immunotherapy for Minimal Residual Disease in Patients With t(8;21) Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation
por: Fan, Shuang, et al.
Publicado: (2022)

PB1800: DEEPDECON: A DEEP-LEARNING METHOD FOR DETECTING MINIMAL RESIDUAL DISEASE OF ACUTE MYELOID LEUKEMIA
por: Zhong, J., et al.
Publicado: (2022)

PB2183: RELAPSE PREDICTS POOR OUTCOMES IN FLT3-MUTATED ACUTE MYELOID LEUKEMIA POST ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION
por: Gavriilaki, E., et al.
Publicado: (2022)

PB2407: ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLO-HSCT) WITH CYCLOPHOSPHAMIDE IN PEDIATRIC HIGH-RISK ACUTE MYELOID LEUKEMIA (HR-AML)
por: Sun, Ming, et al.
Publicado: (2023)

PB2450: SEX-ASSOCIATED OUTCOME DIFFERENCES IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT)
por: Ussmann, Jule, et al.
Publicado: (2023)

PB1806: AZACITIDINE + VENETOCLAX IN PATIENTS WITH ACUTE MYELOID LEUKEMIA, POTENTIAL CANDIDATES TO ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANT – RESULTS FROM A HOSPITAL CENTER
por: Barros Lima, C., et al.
Publicado: (2022)

PB1993: EXPRESSION OF NEO-201 MAY HELP IN THE DIFFERENTIAL DIAGNOSIS BETWEEN MYELODYSPLASTIC SYNDROMES AND ACUTE MYELOID LEUKEMIA
por: Duminuco, Andrea, et al.
Publicado: (2023)

PB1843: DONOR-DERIVED CLL-1 CHIMERIC ANTIGEN RECEPTOR T-CELLS FOR RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA BRIDGING TO ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A CASE REPORT
por: Miao, Xiaojuan, et al.
Publicado: (2023)

PB2203: AGEING OF LONG-TERM ALLOGENEIC HEMATOPOIETIC CELLS RECIPIENTS COMPARED TO THEIR DONORS
por: Czarnogórski, M., et al.
Publicado: (2022)

PB1767: CHALLENGES IN MACHINE LEARNING-BASED DETECTION OF MEASURABLE RESIDUAL DISEASE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA
por: Thielecke, Lars, et al.
Publicado: (2023)

PB1821: COMBINATION OF BCL-2 INHIBITOR, HYPOMETHYLATION AGENTS AND LOW-DOSE CYTARABINE AS A SALVAGE THERAPY FOR ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROMES
por: Gao, X.-N., et al.
Publicado: (2022)

PB2008: INCIDENCE OF DRUG-INDUCED MYELOSUPPRESSION AND ASSOCIATED ADVERSE EVENTS, QUALITY OF LIFE, AND MEDICAL RESOURCE USE IN MYELODYSPLASTIC SYNDROMES AND ACUTE MYELOID LEUKEMIA
por: Nicolae, Maria Vutcovici, et al.
Publicado: (2023)

PB1810: OUTCOME OF ACUTE MYELOID LEUKEMIA RELAPSE AFTER ALLOGENIC STEM CELL TRANSPLANT: A SINGLE INSTITUTION RETROSPECTIVE STUDY
por: Castoldi, C., et al.
Publicado: (2022)

PB2418: CLINICAL FEATURES AND PROGNOSIS OF ADENOVIRUS INFECTION AFTER HAPLOIDENTICAL DONOR HEMATOPOIETIC STEM CELL TRANSPLANTATION
por: Sun, Wei, et al.
Publicado: (2023)

PB2194: ISCHEMIC STROKE IN PATIENTS WITH THROMBOCYTOPENIA AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
por: Pérez Raya, M., et al.
Publicado: (2022)

PB2022: ELTROMBOPAG IN MYELODYSPLASTIC SYNDROME AND CHRONIC MYELOMONOCYTIC LEUKEMIA: A SINGLE-CENTER EXPERIENCE
por: Peña, Amaia Lopez, et al.
Publicado: (2023)

PB1811: REAL LIFE APPLICATION OF NEXT GENERATION SEQUENCING IN ACUTE MYELOID LEUKEMIA AND HIGH RISK MYELODYSPLASTIC SYNDROME PATIENTS: A SINGLE CENTER EXPERIENCE
por: Gabrielli, Giulia, et al.
Publicado: (2023)

PB1997: TRISOMY 18 IN MYELODYSPLASTIC SYNDROMES
por: Abdelmoula, Nouha Bouayed, et al.
Publicado: (2023)

PB2199: A REAL WORLD STUDY OF PEG-RHG-CSF ON HEMATOPOIETIC RECOVERY AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
por: Xu, J., et al.
Publicado: (2022)

PB2338: QUALITY OF LIFE AFTER ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: IMPACT OF CHRONIC GVHD
por: Belloumi, D., et al.
Publicado: (2022)

PB2452: PREVALENCE AND SEVERITY OF COVID-19 IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION PATIENTS IN CHINA
por: Gao, Hongye, et al.
Publicado: (2023)

PB1782: INTEGRATIVE MOLECULAR SUBTYPES OF ACUTE MYELOID LEUKEMIA
por: Mo, Qianxing, et al.
Publicado: (2023)

PB1832: INFLAMMATION INDUCED COAGULATION IN ACUTE MYELOID LEUKEMIA
por: Ajtić, Olivera Mitrović, et al.
Publicado: (2023)

PB1887: STING AGONIST FOR THE TREATMENT OF RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA AND HIGH-RISK MYELODYSPLASTIC SYNDROME: A FIRST-IN-CLINIC PHASE 1 STUDY OF GSK3745417
por: Montesinos, Pau, et al.
Publicado: (2023)

PB2468: A RETROSPECTIVE STUDY OF ELTROMBOPAG IN PATIENTS WITH THROMBOCYTOPENIA AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
por: MA, Liangming, et al.
Publicado: (2023)

PB2424: ORAL VERSUS INTRAVENOUS ANTI-CMV PREEMPTIVE THERAPY IN ALLOGENEIC STEM CELL TRANSPLANT PATIENTS WITH CMV REACTIVATION: EXPERIENCE FROM NATIONAL CENTER OF BONE MARROW TRANSPLANTATION, TUNISIA.
por: Yosra Kanoun, Rimmel, et al.
Publicado: (2023)

PB1844: REAL: A RETROSPECTIVE STUDY OF THE CLINICO-BIOLOGICAL FEATURES OF ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROMES PATIENTS INCLUDED IN AN EARLY PHASE TRIAL AT A COMPREHENSIVE CANCER CENTER.
por: Berton, Guillaume, et al.
Publicado: (2023)

PB1928: ALLOGENEIC STEM CELL TRANSPLANTATION FOR ADULT CHRONIC MYELOMONOCYTIC LEUKEMIA IN THE MOLECULAR ERA
por: Zhang, T.
Publicado: (2022)

PB1847: ACUTE MYELOID LEUKEMIA – IS IT MORE BESIDES GENETIC ABNORMALITIES?
por: Urbano, M., et al.
Publicado: (2022)

PB1900: COVID-19 IMPACT ON CHRONIC MYELOID LEUKEMIA PATIENTS
por: Galdean, S.-M., et al.
Publicado: (2022)

PB1910: CHRONIC MYELOID LEUKEMIA AND RELATIONSHIP TO SECONDARY SOLID NEOPLASMS
por: Ramos, M. J., et al.
Publicado: (2022)

PB1832: ARTERIAL THROMBOSIS AND ACUTE MYELOID LEUKEMIA – IS THERE A CONNECTION?
por: Pantic, N., et al.
Publicado: (2022)

PB1807: THE SIGNIFICANCE OF MOLECULAR RISK FACTORS IN ACUTE MYELOID LEUKEMIA
por: Gordienko, Alla, et al.
Publicado: (2023)

PB1806: ULTRA-SENSITIVE MINIMAL RESIDUAL DISEASE (MRD) MONITORING FOR LEUKEMIA PATIENTS USING SUPERRCA MUTATION ASSAYS WITH FLOW CYTOMETER READOUT
por: Chen, Lei, et al.
Publicado: (2023)

Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis
por: Buckley, Sarah A., et al.
Publicado: (2017)

PB1801: MYCN IS REQUIRED FOR MAINTAINING AN ONCOGENIC CHARACTERISTICS OF LEUKEMIA CELLS IN ACUTE MYELOID LEUKEMIA
por: Huang, Nanfang, et al.
Publicado: (2023)

PB2015: DIAGNOSIS, CLASSIFICATION AND STRATIFICATION OF MYELODYSPLASTIC SYNDROMES IN ALGERIA
por: Moussa, Yamina Bouchakour, et al.
Publicado: (2023)

PB2020: OUTCOMES OF PATIENTS WITH HIGH RISK MYELODYSPLASTIC SYNDROMES
por: Amor, Imen Ben, et al.
Publicado: (2023)

PB2025: CULTURAL DATA TO NEW CLASSIFICATION OF MYELODYSPLASTIC NEOPLASIA
por: Saralidze, Tamar, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_fa44of2sd5o9ojlc44k7ldi5v9